🇺🇸 FDA
Pipeline program

ARQ-252 cream 0.3%

ARQ-252-213

Phase 2 small_molecule terminated

Quick answer

ARQ-252 cream 0.3% for Vitiligo is a Phase 2 program (small_molecule) at Arcutis Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcutis Biotherapeutics
Indication
Vitiligo
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials